Does the media prefer IONS or BIIB?

In the previous week, Ionis Pharmaceuticals had 6 more articles in the media than Biogen. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 23 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Ionis Pharmaceuticals' score of 0.25 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Biogen 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALNY or IONS?

In the previous week, Ionis Pharmaceuticals had 13 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 16 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.25 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IONS or INSM?

In the previous week, Ionis Pharmaceuticals had 18 more articles in the media than Insmed. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 11 mentions for Insmed. Insmed's average media sentiment score of 1.00 beat Ionis Pharmaceuticals' score of 0.25 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Insmed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or BNTX?

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than BioNTech. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 10 mentions for BioNTech. Ionis Pharmaceuticals' average media sentiment score of 0.25 beat BioNTech's score of 0.23 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INCY or IONS?

In the previous week, Ionis Pharmaceuticals had 17 more articles in the media than Incyte. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 12 mentions for Incyte. Incyte's average media sentiment score of 1.25 beat Ionis Pharmaceuticals' score of 0.25 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Ionis Pharmaceuticals (IONS) Competitors

$56.71 -1.38 (-2.38%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$56.40 -0.31 (-0.54%)

As of 05:41 AM Eastern

Compare

IONS vs. BIIB, ALNY, INSM, BNTX, and INCY

Should you buy Ionis Pharmaceuticals stock or one of its competitors? Ionis Pharmaceuticals's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Biogen?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Ionis Pharmaceuticals currently has a consensus target price of $91.50, indicating a potential upside of 61.35%. Biogen has a consensus target price of $228.50, indicating a potential upside of 7.53%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.98	-$381.39M	-$3.46	N/A
Biogen	$9.89B	3.17	$1.29B	$5.65	37.61

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

In the previous week, Ionis Pharmaceuticals had 6 more articles in the media than Biogen. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 23 mentions for Biogen. Biogen's average media sentiment score of 1.02 beat Ionis Pharmaceuticals' score of 0.25 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biogen	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	9.37	$313.75M	$5.38	48.35
Ionis Pharmaceuticals	$944M	9.98	-$381.39M	-$3.46	N/A

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Ionis Pharmaceuticals' net margin of -64.76%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Ionis Pharmaceuticals had 13 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 16 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.25 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus target price of $382.96, suggesting a potential upside of 47.23%. Ionis Pharmaceuticals has a consensus target price of $91.50, suggesting a potential upside of 61.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Insmed?

Ionis Pharmaceuticals (NASDAQ:IONS) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Ionis Pharmaceuticals currently has a consensus price target of $91.50, suggesting a potential upside of 61.35%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 64.56%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ionis Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Ionis Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.98	-$381.39M	-$3.46	N/A
Insmed	$606.42M	44.97	-$1.28B	-$4.11	N/A

Ionis Pharmaceuticals has a net margin of -64.76% compared to Insmed's net margin of -76.94%. Ionis Pharmaceuticals' return on equity of -111.08% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Ionis Pharmaceuticals had 18 more articles in the media than Insmed. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 11 mentions for Insmed. Insmed's average media sentiment score of 1.00 beat Ionis Pharmaceuticals' score of 0.25 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Insmed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to BioNTech?

Ionis Pharmaceuticals (NASDAQ:IONS) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Ionis Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.98	-$381.39M	-$3.46	N/A
BioNTech	$2.65B	9.41	-$1.29B	-$7.83	N/A

BioNTech has a net margin of -63.54% compared to Ionis Pharmaceuticals' net margin of -64.76%. BioNTech's return on equity of -6.86% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
BioNTech	-63.54%	-6.86%	-6.00%

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than BioNTech. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 10 mentions for BioNTech. Ionis Pharmaceuticals' average media sentiment score of 0.25 beat BioNTech's score of 0.23 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ionis Pharmaceuticals currently has a consensus target price of $91.50, suggesting a potential upside of 61.35%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 27.71%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Summary

Ionis Pharmaceuticals beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.33	$1.29B	$7.85	15.85
Ionis Pharmaceuticals	$944M	9.98	-$381.39M	-$3.46	N/A

97.0% of Incyte shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has a net margin of 27.71% compared to Ionis Pharmaceuticals' net margin of -64.76%. Incyte's return on equity of 29.93% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Ionis Pharmaceuticals had 17 more articles in the media than Incyte. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 12 mentions for Incyte. Incyte's average media sentiment score of 1.25 beat Ionis Pharmaceuticals' score of 0.25 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Incyte presently has a consensus target price of $124.05, suggesting a potential downside of 0.28%. Ionis Pharmaceuticals has a consensus target price of $91.50, suggesting a potential upside of 61.35%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

Incyte beats Ionis Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.65B	$4.01B	$7.39B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-16.39	12.50	270.75	25.39
Price / Sales	9.98	1,428.33	646.22	96.55
Price / Cash	N/A	108.60	77.07	52.39
Price / Book	18.78	16.11	10.92	6.40
Net Income	-$381.39M	-$22.81M	$3.48B	$358.18M
7 Day Performance	-7.53%	-0.67%	-0.85%	0.07%
1 Month Performance	0.27%	4.99%	3.03%	-0.78%
1 Year Performance	-11.94%	47.28%	22.29%	12.49%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.4108 of 5 stars	$56.71 -2.4%	$91.50 +61.3%	-7.0%	$9.65B	$944M	N/A	1,402	Trending News Analyst Forecast Gap Down High Trading Volume
BIIB Biogen	3.7239 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+50.3%	$32.28B	$10.03B	38.35	7,500	Positive News Gap Down
ALNY Alnylam Pharmaceuticals	4.6013 of 5 stars	$240.69 +1.5%	$386.14 +60.4%	-42.8%	$31.73B	$4.80B	44.74	2,770	Positive News Analyst Forecast
INSM Insmed	3.8552 of 5 stars	$121.82 +2.8%	$205.52 +68.7%	-14.9%	$25.89B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.6592 of 5 stars	$101.61 -0.5%	$127.44 +25.4%	-3.9%	$25.81B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. BIIB, ALNY, INSM, BNTX, and INCY

How does Ionis Pharmaceuticals compare to Biogen?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. BIIB, ALNY, INSM, BNTX, and INCY

How does Ionis Pharmaceuticals compare to Biogen?

Do analysts rate IONS or BIIB?

Is IONS or BIIB more profitable?

Which has higher earnings & valuation, IONS or BIIB?

Which has more risk & volatility, IONS or BIIB?

Does the media prefer IONS or BIIB?

Do insiders & institutionals believe in IONS or BIIB?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Which has higher valuation and earnings, ALNY or IONS?

Is ALNY or IONS more profitable?

Does the media refer more to ALNY or IONS?

Do insiders and institutionals have more ownership in ALNY or IONS?

Which has more risk and volatility, ALNY or IONS?

Do analysts recommend ALNY or IONS?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Do analysts prefer IONS or INSM?

Which has more volatility and risk, IONS or INSM?

Which has stronger valuation and earnings, IONS or INSM?

Is IONS or INSM more profitable?

Does the media refer more to IONS or INSM?

Do institutionals and insiders hold more shares of IONS or INSM?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Which has more risk & volatility, IONS or BNTX?

Which has stronger earnings & valuation, IONS or BNTX?

Is IONS or BNTX more profitable?

Does the media refer more to IONS or BNTX?

Do institutionals and insiders have more ownership in IONS or BNTX?

Do analysts prefer IONS or BNTX?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Which has stronger earnings & valuation, INCY or IONS?

Do institutionals & insiders have more ownership in INCY or IONS?

Is INCY or IONS more profitable?

Does the media favor INCY or IONS?

Do analysts prefer INCY or IONS?

Which has more volatility & risk, INCY or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools